Summary of the current study and previous studies on PGE1 therapy, as well as natural history studies on CRAO
| N | Age (years) | Time from onset | BCVA (LogMAR) | First visit | 1 month | >3 months | Features | Complication | Type of ischaemia | |
| Current | 21 | 73.3±11.1 | 54.7±76.3 | 2.18±0.60 | 1.54±0.84 | 1.53±0.88 | Lipo-PGE1 10 µg intravenous/day×7–14 days | Nothing | Non-arteritic without cilioretinal artery sparing or transient with FA | |
| Takai et al22 | 6 | 69.3±15.1 | 8.3±3.4* | 2.57±0.18* | 1.62±0.86 | –† | Free PGE1 80 µg intravenous/day×3–5 days | Angialgia | Non-arteritic without cilioretinal artery sparing through appearance | |
| Kreutz et al21 | 10 | 61.3±11.0* | 7.1±5.9* | 2.40±0.30 | 0.55±0.67* | –† | Free PGE1 80 µg intravenous/day×5 days+30 µg po/day×more than 1 month | Angialgia | –† | |
| Chen et al27 | 171 | 67.7±12.3 | >10.4 | 2.34±0.51 | –† | 2.24±0.63 | Natural history | –† | Non-arteritic without cilioretinal artery sparing or transient |
Classical treatment: intraocular pressure-lowering agents (topical timolol 0.5%, oral methazolamide 50 mg), and vascular dilation agent (sublingual isosorbide dinitrate).
*Significantly different from the current study (p<0.05)
†Not listed.
BCVA, best-corrected visual acuity; CRAO, central retinal artery occlusion; FA, fluorescein angiography; lipo-PGE1, liposomal prostaglandin E1; LogMAR, logarithm of the minimal angle of resolution; po, per os.